Literature DB >> 8292455

A patient with cardiac amyloidosis presenting a rapid increase in technetium-99m-hydroxymethylene diphosphonate accumulation.

T Kobayashi1, M Sekiya, Y Fujiwara, T Sumimoto, H Matsuoka, M Hamada, K Hiwada.   

Abstract

We assessed the changes in cardiac condition in a patient with cardiac amyloidosis, by means of dual nuclei single photon emission computed tomographic (SPECT) images with technetium-99m-hydroxymethylene diphosphonate (99mTc-HMDP) and thallium-201 (201Tl). Dual SPECT showed a marked increase in myocardial 99mTc-HMDP accumulation along with deterioration of symptoms and signs, while 201Tl scintigraphy remained almost unchanged.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8292455     DOI： 10.1007/BF03164710

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN： 0914-7187            Impact factor:   2.668


  13 in total

1.  Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis.

Authors:  A L Klein; L K Hatle; C P Taliercio; C L Taylor; R A Kyle; K R Bailey; J B Seward; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

2.  Scanning for soft-tissue amyloid.

Authors:  R W Kula; W K Engel; B R Line
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

3.  Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy.

Authors:  M Hongo; J Hirayama; T Fujii; H Yamada; S Okubo; S Kusama; S Ikeda
Journal:  Am Heart J       Date:  1987-03       Impact factor: 4.749

4.  Is technetium-99 m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis?

Authors:  A Hartmann; J Frenkel; R Hopf; R P Baum; G Hör; M Schneider; M Kaltenbach
Journal:  Int J Card Imaging       Date:  1990

5.  Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model.

Authors:  J A Bevan; A J Tofe; J J Benedict; M D Francis; B L Barnett
Journal:  J Nucl Med       Date:  1980-10       Impact factor: 10.057

6.  Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy.

Authors:  M Hongo; S Ikeda
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

Review 7.  Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy.

Authors:  J T Willerson; R W Parkey; F J Bonte; S E Lewis; J Corbett; L M Buja
Journal:  Semin Nucl Med       Date:  1980-01       Impact factor: 4.446

8.  M-mode and two-dimensional echocardiographic features in cardiac amyloidosis.

Authors:  A G Siqueira-Filho; C L Cunha; A J Tajik; J B Seward; T T Schattenberg; E R Giuliani
Journal:  Circulation       Date:  1981-01       Impact factor: 29.690

9.  Bone scan in systemic amyloidosis.

Authors:  R Roselló; F Lomeña; F Pons; M Grau; M Solé; C Paré; A Catafau; R Herranz
Journal:  Nucl Med Commun       Date:  1988-11       Impact factor: 1.690

Review 10.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616
View more
  2 in total

Review 1.  Nuclear imaging in cardiac amyloidosis.

Authors:  A W J M Glaudemans; R H J A Slart; C J Zeebregts; N C Veltman; R A Tio; B P C Hazenberg; R A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-21       Impact factor: 9.236

Review 2.  Nuclear imaging of amyloidosis.

Authors:  Wojciech Cytawa; Jacek Teodorczyk; Piotr Lass
Journal:  Pol J Radiol       Date:  2014-07-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.